Cardiac Drug Screening with ValaDATE.AI™ & proph𝔼CG™
We deliver unmatched predictivity for drug-induced cardiotoxicity and efficacy, surpassing traditional preclinical models, including animal studies.
Why Choose Vala’s Cardiac Screening?
Our fully automated, high-throughput cardiac screening minimizes development risks, reduces costs, and ensures early detection of safety and efficacy issues.
Reduce late-stage drug failures by up to 50%
ValaDATE.AI™ with proph𝔼CG™ outperforms animal studies
Industry-leading Predictivity of >90%
For drug-induced cardiotoxicity and efficacy
Our platform unlocks deeper, actionable insights - dynamic cellular activity from up to 1,000 cardiomyocytes per well at millisecond resolution
Access the Leading Human Cardiac Toxicity Assessment
Experience the most advanced and clinically predictive in vitro human cardiotoxicity assay available. ValaDATE.AI™ with proph𝔼CG™ revolutionizes drug safety screening with unmatched accuracy and predictive cardiac safety insights to ensure optimal patient outcomes and minimize drug trial risks.
- Superior Performance – Surpasses hERG assays, CiPA, and other cardiotoxicity tests.
- High Accuracy – 97% clinical predictivity for key cardiac metrics like QT prolongation, arrhythmia, and cardiac arrest.
- Early Detection – Identifies drug-induced ECG and echocardiogram changes before patient exposure.
- Faster & Cost-Effective – Speeds up screening while cutting costs.
- Ethical & Reliable – Uses human-relevant in vitro data, eliminating unreliable animal models.
How ValaDATE.AI™ with proph𝔼CG™ Transforms Cardiac Safety Testing
Powered by Vala’s patented tech, ValaDATE.AI™ with proph𝔼CG™ predicts drug-induced cardiac effects from in vitro data with up to 97% accuracy.